Strategies for Each Business Domain Toward 2027
We aim for sustainable growth by appropriately allocating resources according to the stage of each business and creating an optimal business portfolio.
Alcoholic & Non-Alcoholic Beverages Businesses
Segment’s NOP Growth Rate (CAGR) Mid single digit %
Focus Area
Further evolve product development and marketing to meet consumer needs in terms of taste, health, empathy, etc., and implement pricing strategies while improving brand power
-
Steadily improve unit price through price revision and mix improvement
-
Improve Normalized OP margin and ensure stable growth in EPS contribution
Initiatives up to 2024
-
Strengthened focus brands in response to changing consumer needs
-
Differentiated our products and contributed to society by continually expanding our health science products portfolio
-
Expanded premium products that could be differentiated from other products (including brand expansion from Japan to overseas)
-
Improved productivity of the supply chain through facility investments and digitalization
Initiatives toward 2027
-
Strengthen high-profit categories and products, with a focus on beer, to achieve above-market growth
-
Improve profitability by strengthening the RTD category in Australia and the United States
-
Improve profit margin by accelerating growth of health science beverages and other high-profit products
-
Optimize price management and operations for the US consumption market
Pharmaceuticals Business
Segment’s NOP Growth Rate (CAGR) Mid single digit %
Focus Area
-
Steady growth of global strategic products and continued aggressive R&D investment for future growth to continuously create life changing value
Initiatives up to 2024
-
Grew global strategic products
-
Began clinical trials for KHK4083 (for atopic dermatitis)
-
Continued making investment to further expand our pipeline
Initiatives toward 2027
-
Realize sustainable growth of global strategic products
-
Implement initiatives to apply for KHK4083’s approval in 2026 as a treatment for atopic dermatitis
-
Apply for ziftomenib’s approval in the US and promote clinical trials
Health Science Business
Segment’s Normalized OP level for 2027 18.0-20.0 billion yen
Focus Area
-
Implement initiatives for each brand in developing areas to realize growth that outpaces market growth
Initiatives up to 2024
-
Acquired Blackmores and FANCL. Established a growth strategy in Japan and the Asia-Pacific
-
Agreement on the transfer of Kyowa Hakko Bio Co., Ltd.’s amino acid business and others
-
Expanded the LC-Plasma business
Initiatives toward 2027
-
Realize growth of both Blackmores and FANCL and integrate them as planned to realize cost synergy
-
Kirin Holdings and FANCL will collaborate to establish a strategy toward developing examples of new value creation in inner and outer beauty and a plan to implement it
-
Enhance the value of our proprietary material LC-Plasma and expand its business both in Japan and overseas to achieve profitability by 2025
-
Transfer Kyowa Hakko Bio’s amino acid business and other businesses in 2025